A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00909597

Public ClinicalTrials.gov record NCT00909597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.

Study identification

NCT ID: NCT00909597
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 756 participants

Conditions and interventions

Conditions

Diabetes Mellitus Type 2

Interventions

pioglitazone Drug
taspoglutide Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2009
Primary completion: Oct 31, 2010
Completion: Oct 31, 2010
Last update posted: Nov 1, 2016

2009 – 2010

United States locations

U.S. sites: 57
U.S. states: 26
U.S. cities: 55

Facility	City	State	ZIP	Site status
Not listed	Buena Park	California	90620	—
Not listed	Chino	California	91710	—
Not listed	Los Angeles	California	90057	—
Not listed	Rancho Cucamonga	California	91730	—
Not listed	Roseville	California	95661	—
Not listed	Santa Ana	California	92701	—
Not listed	Chiefland	Florida	32626	—
Not listed	Coral Gables	Florida	33134	—
Not listed	Daytona Beach	Florida	32117	—
Not listed	Panama City	Florida	32401	—
Not listed	Port Charlotte	Florida	33948	—
Not listed	St. Petersburg	Florida	33716	—
Not listed	Winter Park	Florida	32789	—
Not listed	Atlanta	Georgia	30338	—
Not listed	Columbus	Georgia	31904	—
Not listed	Conyers	Georgia	30094	—
Not listed	Roswell	Georgia	30076	—
Not listed	Chicago	Illinois	60607	—
Not listed	Chicago	Illinois	60610-4319	—
Not listed	Springfield	Illinois	62704-1433	—
Not listed	Evansville	Indiana	47714	—
Not listed	Madisonville	Kentucky	42431	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Bethesda	Maryland	20817	—
Not listed	Ayer	Massachusetts	01432	—
Not listed	Waltham	Massachusetts	02453	—
Not listed	Ferndale	Michigan	48220	—
Not listed	Minneapolis	Minnesota	55416	—
Not listed	Biloxi	Mississippi	39531	—
Not listed	Jackson	Mississippi	39216	—
Not listed	Olive Branch	Mississippi	38654	—
Not listed	Grand Island	Nebraska	68803	—
Not listed	Berlin	New Jersey	08009	—
Not listed	Brick	New Jersey	08724	—
Not listed	Toms River	New Jersey	08753	—
Not listed	Trenton	New Jersey	08611	—
Not listed	New York	New York	10021	—
Not listed	Staten Island	New York	10301	—
Not listed	Durham	North Carolina	27713	—
Not listed	Mooresville	North Carolina	28117	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Fargo	North Dakota	58103	—
Not listed	Bend	Oregon	97701	—
Not listed	Medford	Oregon	97504	—
Not listed	Beaver	Pennsylvania	15009	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Scranton	Pennsylvania	18510	—
Not listed	Kingsport	Tennessee	37660	—
Not listed	Dallas	Texas	75230	—
Not listed	Houston	Texas	77074	—
Not listed	Salt Lake City	Utah	84107	—
Not listed	South Burlington	Vermont	05403	—
Not listed	Richmond	Virginia	23226	—
Not listed	Richmond	Virginia	23249	—
Not listed	Spokane	Washington	99202	—
Not listed	Vancouver	Washington	98664	—
Not listed	Waukesha	Wisconsin	53189	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00909597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00909597 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →